CSI Market
Sign In | Register

Poseida Therapeutics Inc (PSTX) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access PSTX Annual Income Statement →
The data below summarizes Poseida Therapeutics Inc's income statement results from Sep 30 2023 to Sep 30 2024, enabling period-by-period comparison of operating performance.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2024)
Q3 2024 		(Jun 30 2024) (Mar 31 2024) (Dec 31 2023) (Sep 30 2023)
Revenues
Total Revenue71.75
Costs & Expenses
Gross Profit71.75
Selling, Administration, Marketing10.09
Depreciation & Amortization1.30
Research and Development Expense41.91
Other Operating Expense / -Income0.00
Total operating costs including COS52.01
Operating income / -loss19.74
Interest Expense2.30
Net Interest Expense / -Income2.30
Other loss / -income-2.83
Total costs & expenses51.47
Income & Taxes
Income / -loss before income taxes20.28
Income taxes expenses / -benefit0.04
Income after income taxes20.24
Income / -loss from continuing operations20.24
Net income / -loss20.24
Income / -loss to shareholder20.24
EBIT22.57
EBITD23.89
EBITDA23.89
Earnings Per Share
Basic EPS (excl. extra items)0.21
Basic Net EPS0.21
Basic shares outstanding (Mill. of Units)97.16
Diluted Net EPS0.21
Diluted average shares (Mill. of Units)98.22
4 historic quarters locked

Sign in to unlock the full Poseida Therapeutics Inc income statement history.

Sign In Create Free Account

About Poseida Therapeutics Inc Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: November 7, 2024
  • Original filing: pstx-20240930.htm

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.